NCT02047344 - Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 7, 2018

Study Completion Date

December 7, 2018

Conditions

Non-small Cell Lung Cancer Stage IV

Interventions

DRUG

Antroquinonol

patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.

Trial Locations (10)

704

National Cheng Kung University Hospitail, Tainan City

18840

Guthrie Clinic, Ltd, Sayre

21287

John Hopkins University, Baltimore

21801

Peninsula Regional Med Center, Salisbury

48202

Henry Ford health system, Detroit

60612

Rush University Medical Center, Chicago

85715

Arizona Clinical Research Center, Tucson

88301

Chang Gung Memorial Hospital-Kaohsiung medical center, Kaohsiung City

94115

UCSF, San Francisco

Unknown

Tri Service General Hospital, Taipei